Integrin Beta Fragment Inhibits sPLA2-IIA Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively inhibit the pro-inflammatory action of human secreted phospholipase A2 type IIA (sPLA2-IIA) through integrin activation, which contributes to inflammation and cell proliferation, as they rely on catalytic activity or specific receptors that are not efficiently targeted.
Innovation Solution
Development of a method involving integrin β fragments, specifically peptides or compounds that bind to sPLA2-IIA, to inhibit its interaction with integrins, using site 2-mediated binding, thereby suppressing sPLA2-IIA-induced activation and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods targeting catalytic activity or M-type receptor are used to inhibit sPLA2-IIA, then inhibition of sPLA2-IIA is attempted, but the inhibition is ineffective because these methods do not block the actual pro-inflammatory pathway through integrin activation
Solution Approach 1:
The patent introduces an integrin β fragment as an intermediary molecule that binds to sPLA2-IIA at site 2, preventing sPLA2-IIA from activating integrins. This intermediary approach blocks the pro-inflammatory pathway by competing for binding to sPLA2-IIA, thereby achieving effective inhibition of inflammation and cell proliferation without targeting catalytic activity or M-type receptor
Solution Approach 2:
The patent extracts and utilizes only the integrin β fragment (specifically the site 2 region) rather than requiring full-length integrin or targeting other sPLA2-IIA pathways. This extracted fragment is sufficient to bind sPLA2-IIA and block its pro-inflammatory action, simplifying the therapeutic approach while maintaining effectiveness
2Measurement precision
If site 2-mediated binding approach is used to inhibit sPLA2-IIA-integrin interaction, then specific inhibition of integrin activation is achieved, but this requires identification and use of specific peptide sequences from integrin β
Solution Approach 1:
The patent segments the integrin β chain to identify and utilize only the critical site 2 region (specific amino acid sequences) that is responsible for binding sPLA2-IIA. This segmentation allows creation of a simplified peptide fragment that retains the essential binding function while reducing complexity compared to using full-length integrin
Solution Approach 2:
The patent applies local quality by focusing on the specific site 2 region of integrin β with unique binding properties. This localized approach identifies the precise amino acid sequence that confers specificity for sPLA2-IIA binding, allowing targeted inhibition without requiring the entire integrin structure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively reduces inflammation and cell proliferation by blocking the binding of sPLA2-IIA to integrins, providing a novel mechanism to target pro-inflammatory actions independent of catalytic activity or M-type receptor binding.
Implementation Method 1
contacting a test compound with sPLA2-IIA and an integrin β fragment, i.e., a polypeptide comprising a site 2 sequence of an integrin β... under conditions that permit specific binding between sPLA2-IIA and the polypeptide
Data Source
AI summary
The present invention relates to the discovery that a secretory phospholipase A2 (sPLA2-IIA) plays an active role in mediating cellular signaling leading to an inflammatory response or cell proliferation by way of its specific binding with integrin β at site 2 of integrin β. More specifically, the invention provides a method for identifying inhibitors of inflammatory or proliferative signaling by screening for compounds that interrupt the specific binding of sPLA2 and integrin β at site 2. The invention also provides the novel use of a substance that suppresses the specific binding between sPLA2 and site 2 of integrinβ for the purpose of treating or preventing a condition involving an undesired inflammatory response or cell proliferation.